Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

医学 乳腺癌 肿瘤科 内科学 癌症 新辅助治疗 事件(粒子物理) 残余物 风险评估 量子力学 算法 计算机安全 物理 计算机科学
作者
W. Fraser Symmans,Christina Yau,Yunn-Yi Chen,Ronald Balassanian,Molly Klein,Lajos Pusztai,Rita Nanda,Barbara A. Parker,Brian Datnow,Gregor Krings,Shi Wei,Michael D. Feldman,Xiuzhen Duan,Beiyun Chen,Husain Sattar,Laila Khazai,Jay Zeck,Sharon B. Sams,Paulette Mhawech‐Fauceglia,Mara H. Rendi
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (11): 1654-1654 被引量:74
标识
DOI:10.1001/jamaoncol.2021.3690
摘要

Importance

Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in neoadjuvant breast cancer trials.

Objective

To compare RCB distributions between randomized control and investigational treatments within subtypes of breast cancer and explore the relationship with survival.

Design, Setting, and Participants

The I-SPY2 is a multicenter, platform adaptive, randomized clinical trial in the US that compares, by subtype, investigational agents in combination with chemotherapy vs chemotherapy alone in adult women with stage 2/3 breast cancer at high risk of early recurrence. Investigational treatments graduated in a prespecified subtype if there was 85% or greater predicted probability of higher rate of pathologic complete response (pCR) in a confirmatory, 300-patient, 1:1 randomized, neoadjuvant trial in that subtype. Evaluation of a secondary end point was reported from the 10 investigational agents tested in the I-SPY2 trial from March 200 through 2016, and analyzed as of September 9, 2020. The analysis plan included modeling of RCB within subtypes defined by hormone receptor (HR) andERBB2 status and compared control treatments with investigational treatments that graduated and those that did not graduate.

Interventions

Neoadjuvant paclitaxel plus/minus 1 of several investigational agents for 12 weeks, then 12 weeks of cyclophosphamide/doxorubicin chemotherapy followed by surgery.

Main Outcomes and Measures

Residual cancer burden (pathological measure of residual disease) and event-free survival (EFS).

Results

A total of 938 women (mean [SD] age, 49 [11] years; 66 [7%] Asian, 103 [11%] Black, and 750 [80%] White individuals) from the first 10 investigational agents were included, with a median follow-up of 52 months (IQR, 29 months). Event-free survival worsened significantly per unit of RCB in every subtype of breast cancer (HR-positive/ERBB2-negative: hazard ratio [HZR], 1.75; 95% CI, 1.45-2.16; HR-positive/ERBB2-positive: HZR, 1.55; 95% CI, 1.18-2.05; HR-negative/ERBB2-positive: HZR, 2.39; 95% CI, 1.64-3.49; HR-negative/ERBB2-negative: HZR, 1.99; 95% CI, 1.71-2.31). Prognostic information from RCB was similar from treatments that graduated (HZR, 2.00; 95% CI, 1.57-2.55; 254 [27%]), did not graduate (HZR, 1.87; 95% CI, 1.61-2.17; 486 [52%]), or were control (HZR, 1.79; 95% CI, 1.42-2.26; 198 [21%]). Investigational treatments significantly lowered RCB in HR-negative/ERBB2-negative (graduated and nongraduated treatments) andERBB2-positive subtypes (graduated treatments), with improved EFS (HZR, 0.61; 95% CI, 0.41-0.93) in the exploratory analysis.

Conclusions and Relevance

In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of subtype and treatment. Effective neoadjuvant treatments shifted the distribution of RCB in addition to increasing pCR rate and appeared to improve EFS. Using a standardized quantitative method to measure response advances the interpretation of efficacy.

Trial Registration

ClinicalTrials.gov Identifier:NCT01042379
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小青蛙OA完成签到,获得积分10
1秒前
蓁蓁发布了新的文献求助10
1秒前
Orange应助hao采纳,获得10
1秒前
量子星尘发布了新的文献求助10
1秒前
cyndi完成签到,获得积分0
4秒前
5秒前
贰鸟应助七月流火采纳,获得10
6秒前
yulia完成签到 ,获得积分10
7秒前
佳期如梦完成签到 ,获得积分10
7秒前
8秒前
阿Q完成签到,获得积分10
9秒前
10秒前
彬琪发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
雨木目完成签到,获得积分10
13秒前
小鱼完成签到,获得积分10
13秒前
chenkaixin发布了新的文献求助10
13秒前
梦XING完成签到 ,获得积分10
14秒前
eternity136发布了新的文献求助10
14秒前
vv完成签到,获得积分10
15秒前
15秒前
哈哈哈哈发布了新的文献求助20
15秒前
KANG完成签到,获得积分10
16秒前
义气黄焖排骨完成签到,获得积分10
16秒前
17秒前
如梦如画发布了新的文献求助10
17秒前
Hannes应助15902933324sjc采纳,获得10
18秒前
18秒前
18秒前
梓默完成签到 ,获得积分10
18秒前
我是老大应助Japan采纳,获得10
19秒前
彬琪完成签到,获得积分10
19秒前
红尘踏歌完成签到,获得积分10
19秒前
不忘初心发布了新的文献求助10
20秒前
18746005898完成签到 ,获得积分10
20秒前
chenkaixin完成签到,获得积分10
21秒前
WangZhen完成签到,获得积分20
22秒前
乔木木完成签到,获得积分10
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066